GWC Technologies Obtains License for Versatile Label-Free Array Surface from WARF
News Jun 26, 2008
GWC Technologies Inc. has announced that it has signed an agreement with the Wisconsin Alumni Research Foundation (WARF) for an exclusive license to a new “carbon-on-metal” surface technology that will allow GWC’s imaging systems to generate reliable data.
Details of the new technology, developed in the laboratory of Dr. Lloyd Smith, chemistry professor at the University of Wisconsin-Madison, recently were published by lead author Matthew Lockett and colleagues in the Journal of the American Chemical Society.
“Carbon-on-metal surfaces, in conjunction with GWC’s label-free array systems, enhance the quality of information that can be obtained in studies of protein function. How proteins function is of great interest in drug discovery and life science research because proteins are central to how living cells are regulated at the molecular level,” explained Smith.
GWC’s scientific instruments use “SPR imaging,” a method of analyzing many proteins at once. SPR imaging does not need the fluorescent tags or other chemical labels that traditional methods of protein analysis require.
Fluorescent tags are problematic, because they can modify protein function, causing experimental artefacts. By contrast, experiments that use GWC’s SPR imaging systems generate data that more accurately reflect protein function, the company claims.
Stephen C. Weibel, GWC’s director of engineering and a co-inventor of the new technology, explained, “The consumable chips utilized in our detection systems have relied on traditional gold surfaces, suitable for use in the research lab. This new and more robust surface allows the development of biochips and chemical sensors for use in medical diagnostics, environmental testing, and agriculture and food monitoring.”
He noted that the new surface is similar to the coating technology used on razor blades. “In addition to enabling the fabrication of high-density bio-chips, the new surfaces also are suitable for mass-spectrometry analysis of proteins captured on our arrays.”
According to GWC’s president and CEO, Tim Burland, the new surfaces will enable the company to implement many assays that are vitally important in drug discovery. Examples include the analysis of DNA-protein interactions on DNA arrays manufactured by so-called “on-chip” synthesis, and the study of protein-drug interactions using small molecule arrays made by combinatorial chemistry. He added that the company will be seeking corporate partners to bring the technology to the broadest possible market as quickly as possible.
Measuring Neutrophil Motility Could Lead to Accurate Sepsis DiagnosisNews
Mass. General researchers design device that rapidly diagnoses sepsis with more than 95 percent accuracy.READ MORE
Largest Genetic Study of Osteoarthritis Advances ResearchNews
Osteoarthritis is a complex disease, and the genetic basis of the disease has proved difficult to pin down. A new study from the Sanger Institute provides much-needed hope.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
11th International Conference and Exhibition on Metabolomics & Systems Biology
May 17 - May 19, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018